ZS Pharma, a Coppell, TX-based specialty pharmaceutical company developing novel treatments for kidney, cardiovascular, and liver disorders, completed a $55m Series D financing.
The round was led by Novo A/S with participation from new investors RA Capital, Adage Capital, Sofinnova Ventures, and existing investors Alta Partners, Devon Park Bioventures, 3×5 Special Opportunity Fund, Salem Partners and RiverVest.
Led by Robert Alexander, Ph.D., Chairman and CEO, and Alvaro Guillem, Ph.D., President, ZS Pharma is developing ZS-9 to demonstrate its ability to safely and effectively remove excess potassium from the blood and maintain normal potassium levels and is also pursuing the discovery of additional drug candidates that utilize its novel selective ion-trap technology for the treatment of kidney and liver diseases.
The company intends to use the funds to advance development of ZS-9, its lead product candidate for the treatment of hyperkalemia, through its New Drug Application (NDA) and Marketing Authorization Application (MAA) submissions in early 2015.
FinSMEs
06/03/2014